Erratum: Effects of exogenous recombinant APC in mouse models of ischemia reperfusion injury and of atherosclerosis (PLoS ONE (2014) 9, 7 (e101446) DOI: 10.1371/journal.pone.0101446);Effects of exogenous recombinant APC in mouse models of ischemia reperfusion injury and of atherosclerosis

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Wildhagen, Karin C A A ^a   Schrijver, Roy ^a   Beckers, Linda ^b   Ten Cate, Hugo ^a,c   Reutelingsperger, Chris P M ^a   Lutgens, Esther ^b   Nicolaes, Gerry A F ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; RECOMBINANT PROTEIN; APOLIPOPROTEIN E; CCL2 PROTEIN, MOUSE; CELL SURFACE RECEPTOR; IL10 PROTEIN, MOUSE; INTERLEUKIN 10; LEUKOCYTE ANTIGEN; PROCR PROTEIN, HUMAN; PROTEIN C; PROTEINASE ACTIVATED RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFECT; HEART INFARCTION; HEART INFARCTION LOCALIZATION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; MOUSE; MOUSE MODEL; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REPERFUSION INJURY; SHAM PROCEDURE; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TISSUE HOMOGENATE; UPREGULATION; ANIMAL; BLOOD; C57BL MOUSE; CELL LINE; CELL PROTECTION; DRUG EFFECTS; GENETICS; HEART; HEK293 CELL LINE; HUMAN; KNOCKOUT MOUSE; MALE; METABOLISM; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY;

ANIMALS; ANTIGENS, CD; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL LINE; CHEMOKINE CCL2; CYTOPROTECTION; HEART; HEK293 CELLS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; PROTEIN C; RECEPTOR, PAR-1; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; REPERFUSION INJURY;

EID: 84904479731     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109498     Document Type: Erratum

References (74)

1. Stearns-Kurosawa D, Kurosawa S, Mollica J, Ferrell G, Esmon C (1996) The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. PNAS 96: 10212-10216. (Pubitemid 26314601)
2. Kalafatis M, Rand M, Mann K (1994) The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 269: 31869-31880. (Pubitemid 24379561)
3. Fay P, Smudzin T, Walker F (1991) Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem 266: 20139-20145. (Pubitemid 21908437)
4. Nicolaes GAF, Dahlbäck B (2002) Factor V and thrombotic disease: description of a janus-faced protein. Arterioscler Thromb Vasc Biol 22: 530-538. (Pubitemid 34408730)
5. Nicolaes G, Dahlbäck B (2003) Activated protein C resistance (FV(Leiden)) and thrombosis: factor V mutations causing hypercoagulable states. Hematol Oncol Clin North Am 17: 37-61. (Pubitemid 36206063)
6. Broekmans AW, Veltkamp JJ, Bertina RM (1983) Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med 309: 340-344.
7. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Widerman C (1981) Deficiency of protein C in congenital thrombotic disease. J Clin Invest 68: 1370-1373. (Pubitemid 12235040)
8. Marlar RA, Montgomery RR, Broekmans AW (1989) Diagnosis and treatment of homozygous protein C deficiency. Report of the Working Party on Homozygous Protein C Deficiency of the Subcommittee on Protein C and Protein S, International Committee on Thrombosis and Haemostasis. J Pediatr 114: 528-534. (Pubitemid 19098280)
9. Seligsohn U, Berger A, Abend M, Rubin L, Attias D, et al. (1984) Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med 310: 559-562. (Pubitemid 14193095)
10. Bae J, Yang L, Rezaie A (2007) Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells. Proc Natl Acad Sci USA 104: 2867-2872. (Pubitemid 46327971)
11. Mosnier LO, Zlokovic BV, Griffin JH (2007) The cytoprotective protein C pathway. Blood 109: 3161-3172. (Pubitemid 46572500)
12. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, et al. (1996) Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 87: 642-647. (Pubitemid 26030319)
13. Zlokovic B, Zhang C, Liu D, Fernandez J, Griffin J, et al. (2005) Functional recovery after embolic stroke in rodents by activated protein C. Ann Neurol 58: 474-477. (Pubitemid 41266637)
14. Loubele ST, Spek CA, Leenders P, van Oerle R, Aberson HL, et al. (2009) Activated protein C protects against myocardial ischemia/reperfusion injury via inhibition of apoptosis and inflammation. Arterioscler Thromb Vasc Biol 29: 1087-1092.
15. Fernandez JA, Xu X, Liu D, Zlokovic BV, Griffin JH (2003) Recombinant murine activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells Mol Diseases 30: 271-276. (Pubitemid 36539428)
16. Taylor Fj, Chang A, Esmon C, D'Angelo A, Vigano-D'Angelo S, et al. (1987) Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 79: 918-925.
17. Gale AJ, Sun X, Heeb MJ, Griffin JH (1997) Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va. Protein science 6: 132-140. (Pubitemid 27045252)
18. Nicolaes GAF, Bock PE, Segers K, Wildhagen KCAA, Dahlbäck B, et al. (2010) Inhibition of thrombin formation by active site mutated (S360A) activated protein C. J Biol Chem 285: 22890-22900.
19. Mosnier LO, Gale AJ, Yegneswaran S, Griffin JH (2004) Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood 104: 1740-1744. (Pubitemid 39202282)
20. Ludeman M, Kataoka H, Srinivasan Y, Esmon N, Esmon C, et al. (2005) PAR1 cleavage and signaling in response to activated protein C and thrombin. J Biol Chem 280: 13122-13128.
21. Bae J, Yang L, Rezaie A (2008) Lipid raft localization regulates the cleavage specificity of protease activated receptor 1 in endothelial cells. J Thromb Haemost 6: 954-961. (Pubitemid 351689917)
22. Krisinger M, Guo LJ, Salvagno G, Guidi GC, Lippi G, et al. (2009) Mouse recombinant protein C variants with enhanced membrane affinity and hyper-anticoagulant activity in mouse plasma. FEBS J 276: 6586-6602.
23. Wang J, Yang L, Rezaie A, Li J (2011) Activated protein C protects against myocardial ischemic/reperfusion injury through AMP-activated protein kinase signaling. J Thromb Haemost 9: 1308-1317.
24. Guo H, Wang Y, Singh I, Liu D, Fernandez JA, et al. (2009) Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity. J Neurochem 109: 116-124.
25. Park SW, Chen SW, Kim M, D'Agati VD, Lee HT (2009) Human activated protein C attenuates both hepatic and renal injury caused by hepatic ischemia and reperfusion injury in mice. Kidney Int 76: 739-750.
26. Shibata M, Kumar SR, Amar A, Fernandez JA, Hofman F, et al. (2001) Anti-inflammatory, antithrombotic and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation 103: 1799-1805. (Pubitemid 32291419)
27. Sopel M, Rosin N, Falkenham A, Bezuhly M, Esmon C, et al. (2012) Treatment with activated protein C (aPC) is protective during the development of myocardial fibrosis: an angiotensin II infusion model in mice. PLoS One 7: e45663.
28. Yellon D, Hausenloy D (2007) Myocardial Reperfusion Injury. N Engl J Med 257: 1121-1135.
29. Libby P (2010) Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 32: 2045-2051.
30. Sun YH, Shen L, Dahlbäck B (2003) Gla domain-mutated human protein C exhibiting enhanced anticoagulant activity and increased phospholipid binding. Blood 101: 2277-2284. (Pubitemid 36302070)
31. Friedrich U, Pötzsch B, Preissner K, Müller-Berghaus G, Ehrlich H (1994) Calcium-dependent activation of protein C by thrombin/thrombomudulin: role of negatively charged amino acids within the activation peptide of protein C. Thromb Haemost 72: 567-572. (Pubitemid 24305652)
32. Thiyagarajan M, Fernández J, Lane S, Griffin J, Zlokovic B (2008) Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1. J Neurosci 28: 12788-12797.
33. Cheng T, Dong L, Griffin J, Fernandez J, Castellino F, et al. (2003) Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 9: 338-342. (Pubitemid 36362790)
34. Jong W, Reitsma P, ten Cate H, de Winter R (2003) Modified two-step model for studying the inflammatory response during myocardial ischemia and reperfusion in mice. Comp Med 53: 522-526. (Pubitemid 37433248)
35. Erlich J, Boyle E, Labriola J, Kovacich J, Santucci R, et al. (2000) Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am J Pathol 157: 1849-1862.
36. Virmani R, Kolodgie F, Burke A, Farb A, Schwartz S (2000) Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20: 1262-1275. (Pubitemid 30262927)
37. Donners M, Beckers L, Lievens D, Munnix I, Heemskerk J, et al. (2008) The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling. Blood 111: 4596-4604.
38. Biasucci L, Vitelli A, Liuzzo G, Alltamura S, Caligiuri G, et al. (1996) Elevated Levels of Interleukin-6 in Unstable Angina. Circulation 94: 874-877. (Pubitemid 26292834)
39. Maehata Y, Miyagawa S, Sawa Y (2012) Activated protein C has a protective effect against myocardial I/R injury by improvement of endothelial function and activation of AKT1. PLoS One 7: e38738.
40. Lay W, Rayner B, Sabaretnam T, Figtree G, Jackson C, et al. (2012) Activated protein C improves left ventricular remodelling after ischemia-reperfusion injury in rats. Int J Cardiol 159: 246-248.
41. Ding J, Tong X, Yang J, Liu Z, Zhang Y, et al. (2010) Activated protein C protects myocardium via activation of anti-apoptotic pathways of survival in ischemia-reperfused rat heart. J Korean Med Sci 25: 1609-1615.
42. Pirat B, Muderrisoglu H, Unal M, Ozdemir H, Yildirir A, et al. (2006) Recombinant human-activated protein C inhibits cardiomyocyte apoptosis in a rat model of myocardial ischemia-reperfusion. Coron Artery Dis 18: 61-66. (Pubitemid 44973758)
43. Loubele S, Spek C, Leenders P, Hamulyák K, Matthijsen R, et al. (2009) The anti-coagulants ASIS and APC do not protect against renal I/R injury. Inhibition of ischemic organ damage with anti-coagulant agents. Maastricht: Thesis Maastricht University. 91-111.
44. Borissoff J, Otten J, Heeneman S, Leenders P, van Oerle R, et al. (2013) Genetic and pharmacological modifications of thrombin formation in apolipoprotein edeficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner. PLoS One 8: e55784.
45. Wang Y, Zhang Z, Chow N, Davis T, Griffin J, et al. (2012) An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. Stroke 43: 2444-2449.
46. Brückner M, Lasarzik I, Jahn-Eimermacher A, Peetz D, Werner C, et al. (2013) High dose infusion of activated protein C (rhAPC) fails to improve neuronal damage and cognitive deficit after global cerebral ischemia in rats. Neurosci Lett 551: 28-33.
47. Lin X, Li Y, Mei G, Zou F, He D, et al. (2009) Activated protein C can be used as a prophylactic as well as a therapeutic agent for heat stroke in rodents. Shock 32: 524-529.
48. Chen C, Hou C, Cheng K, Tian R, Chang C, et al. (2006) Activated protein C therapy in a rat heat stroke model. Crit Care Med 34: 1960-1966. (Pubitemid 43982474)
49. Teschendorf P, Albertsmeier M, Vogel P, Padosch S, Spöhr F, et al. (2008) Neurological outcome and inflammation after cardiac arrest-effects of protein C in rats. Resuscitation 79: 316-324.
50. Teschendorf P, Padosch S, Del Valle Y, Fuentes D, Peter C, et al. (2009) Effects of activated protein C on post cardiac arrest microcirculation: an in vivo microscopy study. Resuscitation 80: 940-945.
51. Bae JS, Rezaie AR (2009) Thrombin inhibits nuclear factor kB and RhoA pathways in cytokine-stimulated vascular endothelial cells when EPCR is occupied by protein C. Thromb Haemost 101: 513-520.
52. Bae J, Rezaie A (2008) Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand. Thromb Haemost 100: 101-109. (Pubitemid 351948751)
53. Bae J, Yang L, Manithody C (2007) The ligand occupancy of endothelial protein C receptor switches the PAR-1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 110: 3909-3916. (Pubitemid 350248446)
54. Feistritzer C, Schuepbach R, Mosnier L, Bush L, Di Cera E, et al. (2006) Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J Biol Chem 281: 20077-20084. (Pubitemid 44065782)
55. Preston R, Villegas-Mendez A, Sun Y, Hermida J, Simioni P, et al. (2005) Selective modulation of protein C affinity for EPCR and phospholipids by Gla domain mutation. FEBS J 272: 97-108. (Pubitemid 40083070)
56. Yamaji K, Wang Y, Liu Y, Abeyama K, Hashiguchi T, et al. (2005) Activated protein C, a natural anticoagulant protein, has antioxidant properties and inhibits lipid peroxidation and advanced glycation end products formation. Thromb Res 115: 319-325.
57. Bock F, Shahzad K, Vergnolle N, Isermann B (2014) Activated protein C based therapeutic strategies in chronic diseases. Thromb Haemost 111: 610-617.
58. Raedschelders K, Ansley D, Chen D (2012) The cellular and molecular origin of reactive oxygen species generation during myocardial ischemia and reperfusion. Pharmacol Ther 133: 230-255.
59. Iqbal K, Rauoof M, Mir M, Tramboo N, Malik J, et al. (1987) Lipid peroxidation during acute coronary syndromes and its intensification at the time of myocardial ischemia reperfusion. Am J Cardiol 89: 334-337.
60. Hirose K, Okajima K, Taoka Y, Uchiba M, Tagami H, et al. (2000) Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation. Ann Surg 232: 272-280. (Pubitemid 30616729)
61. Wang Y, Sinha R, Mosnier L, Griffin J, Zlokovic B (2013) Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice. Blood Cells Mol Dis 51: 104-108.
62. Guo H, Liu D, Gelbard H, Cheng T, Insalaco R, et al. (2004) Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron 41: 563-572. (Pubitemid 38253068)
63. Zhong Z, Ilieva H, Hallagan L, Bell R, Singh I, et al. (2009) Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest 119: 3437-3449.
64. Galley H, El Sakka N, Webster N, Lowes D, Cuthbertson B (2008) Activated protein C inhibits chemotaxis and interleukin-6 release by human neutrophils without affecting other neutrophil functions. Br J Anaesth 100: 815-819. (Pubitemid 351774323)
65. van Lenten B, Wagner A, Navab M, Fogelman A (2001) Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem 276: 1923-1929. (Pubitemid 32109669)
66. Song L, Schindler C (2004) IL-6 and the acute phase response in murine atherosclerosis. Atherosclerosis 177: 43-51. (Pubitemid 39361137)
67. Keidar s, Heinrich R, Kaplan M, Heayek T, Aviram M (2001) Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: a possible role for interleukin-6. Thromb Vasc Biol 21: 1464-1469.
68. Huber S, Sakkinen P, Conze D, Hardin N, Tracy R (1999) Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 19: 2364-2367. (Pubitemid 29477837)
69. Nakashima Y, Plump A, Raines E, Breslow J, Ross R (1994) ApoE-deficient mice develop lesions in all phases of atherosclerosis throughout the arterial tree. Ateroscler Thromb 14: 133-140.
70. Elhage R, Clamens S, Besnard S, Mallat Z, Tedgui A, et al. (2001) Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17beta-estradiol in apolipoprotein E-deficient mice. Atherosclerosis 156: 315-320. (Pubitemid 32522911)
71. Spagnoli L, Bonanno E, Sangiorgi G, Mauriello A (2007) Role of Inflammation in Atherosclerosis. J Nucl Med 48: 1800-1815. (Pubitemid 350099325)
72. Hansson G (2001) Immune Mechanisms in Atherosclerosis. Arterioscler Thromb Vasc Biol 21: 1876-1890.
73. Petäjä J, Pesonen E, Fernández J, Vento A, Rämö O, et al. (1999) Cardiopulmonary bypass and activation of antithrombotic plasma protein C. J Thorac Cardiovasc Surg 118: 422-429.
74. Boisclair M, Lane D, Philippou H, Sheikh S, Hunt B (1993) Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1+2. Thromb Haemost 70: 253-258. (Pubitemid 23222479)